Cell-penetrating peptides for siRNA delivery to glioblastomas (2018)
Sequence: Stearyl-WLRLWRRWLRLWTFFYGGSRGKRNNFKTEEY-NH2
| Experiment Id | EXP000900 |
|---|---|
| Paper | Cell-penetrating peptides for siRNA delivery to glioblastomas |
| Peptide | PF52 (PepFect 52) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 25 nM |
| Mixing Ratio | MR 5–50 tested |
| Formulation Format | peptide/siRNA non-covalent nanocomplex |
| Formulation Components | |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87 MG-luc2 (human glioblastoma); HeLa-luc used as non-glioma control in supplemental experiments |
| Animal Model | |
| Administration Route | |
| Output Type | luciferase knockdown |
| Output Value | |
| Output Units | |
| Output Notes | Luciferase assay in U87 MG-luc2 at 25 nM siRNA across MRs (Fig.2); numerical % knockdown not explicitly stated in text. |
| Toxicity Notes | No significant toxicity reported in U87 MG-luc2 at 25 nM siRNA (WST-1, 24 h) across tested MRs for all peptide:siRNA complexes. |
| Curation Notes |